Quality of life

  • G. Teeling Smith
Chapter

Abstract

The aims of this paper are threefold. First, to describe why it is becoming increasingly important to measure the effect of modern therapy on the quality of patients’ lives. Second, to explain briefly the economic techniques which are being developed to produce these measurements. And third, to describe the problems which exist at the present stage in the development of these new techniques. The conclusion will be that the measurement of quality of life during and after the clinical evaluation of a new medicine will become increasingly essential during the 1990s. However a great deal of economic research, in collaboration with clinicians and pharmaceutical physicians, is still necessary before current methods of measurement can be regarded as routine and reliable ‘instruments’ in the evaluation of new therapies.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. [1]
    Office of Health Economics. Progress Against Tuberculosis, London: Office of Health Economics, 1962.Google Scholar
  2. [2]
    Teeling Smith G, Wells N E J. The economic contribution of the industry in England and Wales. Pharm J 1985;235:178–9.Google Scholar
  3. [3]
    Office of Health Economics. Sickness Absence; a Review, London: Office of Health Economics, 1981.Google Scholar
  4. [4]
    Teeling Smith G. Measurement of Health, London: Office of Health Economics, 1985.Google Scholar
  5. [5]
    Buxton M J, et al. Costs and Benefits of the Heart Transplant Programme, London: Her Majesty’s Stationery Office, 1985.Google Scholar
  6. [6]
    Rosser R M. Issues of measurement in the design of health indicators. In: Culger A J ed. Health Indicators, London: Martin Robertson, 1983.Google Scholar
  7. [7]
    Rosser R M. A history of the development of health indicators. In: Teeling Smith G ed. Measuring the social benefits of medicine, London: Office of Health Economics, 1984.Google Scholar
  8. [8]
    Williams A. Economics of coronary artery bypass grafting. Br Med J 1985;291:326–9.CrossRefGoogle Scholar
  9. [9]
    Cromie B W. The feet of clay of the double-blind trial. Lancet 1963;2:994–7.CrossRefGoogle Scholar

Copyright information

© The International Federation of Associations of Pharmaceutical Physicians 1988

Authors and Affiliations

  • G. Teeling Smith

There are no affiliations available

Personalised recommendations